Upstream Bio, Inc. (UPB): Total Assets
$353.77M
As of 2025-12-31
$281.17M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $353.77M | -26.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $481.72M | +311.0% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $117.20M | n/a | 2025-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | 2025-12-31 | $353.77M | -26.6% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $296.41M | -31.9% |
| Xenetic Biosciences, Inc. (XBIO) | 2025-12-31 | $8.36M | +21.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $37.66M | -3.0% |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $6.34M | -22.2% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $117.81M | +50.4% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $19.07M | -13.4% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $9.98M | +4.3% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $530.92M | +42.0% |
Compare UPB, RNAC, XBIO, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗